Brokers Offer Predictions for Krystal Biotech Q3 Earnings

Key Points

• HC Wainwright has revised its Q3 2025 EPS estimate for Krystal Biotech from $1.58 to $1.06, while maintaining a "Buy" rating with a target price of $240.00.
• The company reported a Q2 earnings per share of $1.29, exceeding the consensus estimate of $1.08, with a net margin of 40.85%.
• Insider Suma Krishnan sold 13,435 shares at an average price of $150.30, representing a 0.92% decrease in her position.

Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) - HC Wainwright lowered their Q3 2025 earnings per share estimates for shares of Krystal Biotech in a research report issued on Monday, August 4th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings per share of $1.06 for the quarter, down from their previous estimate of $1.58. HC Wainwright currently has a "Buy" rating and a $240.00 target price on the stock. The consensus estimate for Krystal Biotech's current full-year earnings is $6.14 per share. HC Wainwright also issued estimates for Krystal Biotech's Q4 2025 earnings at $1.09 EPS, FY2025 earnings at $4.56 EPS, FY2026 earnings at $6.70 EPS, FY2027 earnings at $9.12 EPS and FY2028 earnings at $10.52 EPS.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its earnings results on Monday, August 4th. The company reported $1.29 earnings per share for the quarter, topping analysts' consensus estimates of $1.08 by $0.21. Krystal Biotech had a return on equity of 15.21% and a net margin of 40.85%. The firm had revenue of $96.04 million for the quarter, compared to the consensus estimate of $95.42 million.

Other equities analysts have also recently issued reports about the company. Bank of America cut their price objective on Krystal Biotech from $193.00 to $192.00 and set a "buy" rating for the company in a report on Tuesday, July 22nd. Citigroup restated a "neutral" rating and issued a $166.00 price objective (down from $176.00) on shares of Krystal Biotech in a research note on Tuesday, August 5th. Guggenheim dropped their price objective on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Finally, Chardan Capital reissued a "buy" rating and issued a $219.00 price objective on shares of Krystal Biotech in a research report on Tuesday, August 5th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $210.22.

Krystal Biotech Price Performance

Shares of NASDAQ:KRYS traded down $0.16 during trading on Thursday, hitting $138.50. 110,964 shares of the company were exchanged, compared to its average volume of 333,589. The company has a market cap of $4.01 billion, a PE ratio of 28.15 and a beta of 0.70. The stock has a 50 day moving average of $141.94 and a 200 day moving average of $155.38. Krystal Biotech has a 52-week low of $122.80 and a 52-week high of $207.84.

Institutional Trading of Krystal Biotech

Several institutional investors have recently added to or reduced their stakes in KRYS. LPL Financial LLC raised its holdings in Krystal Biotech by 156.8% in the fourth quarter. LPL Financial LLC now owns 2,946 shares of the company's stock valued at $462,000 after acquiring an additional 1,799 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in Krystal Biotech by 18.7% in the fourth quarter. JPMorgan Chase & Co. now owns 151,835 shares of the company's stock valued at $23,786,000 after acquiring an additional 23,934 shares in the last quarter. Alliancebernstein L.P. raised its holdings in shares of Krystal Biotech by 4.7% during the fourth quarter. Alliancebernstein L.P. now owns 31,120 shares of the company's stock worth $4,875,000 after purchasing an additional 1,400 shares during the period. ExodusPoint Capital Management LP acquired a new stake in shares of Krystal Biotech during the fourth quarter worth $1,529,000. Finally, Wells Fargo & Company MN raised its holdings in shares of Krystal Biotech by 21.3% during the fourth quarter. Wells Fargo & Company MN now owns 16,928 shares of the company's stock worth $2,652,000 after purchasing an additional 2,972 shares during the period. 86.29% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Krystal Biotech

In other news, insider Suma Krishnan sold 13,435 shares of the business's stock in a transaction on Monday, July 14th. The shares were sold at an average price of $150.30, for a total transaction of $2,019,280.50. Following the transaction, the insider directly owned 1,443,276 shares of the company's stock, valued at approximately $216,924,382.80. The trade was a 0.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have sold 49,800 shares of company stock worth $7,487,943 over the last 90 days. Insiders own 13.70% of the company's stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).